Dr J. Purvis MCA-L
Dr F Rotblat MCA-L
Mrs G. Silvester MCA-L
Dr L Tsang MCA-L
Dr A. Rejman HC(M)1
Dr M. Kavanagh MCA-I&E

From: N.M. Goulding MCA-I&E

Date: 24 November 1994.

RECALL OF BLOOD PRODUCTS PRODUCED FROM CJD-AFFECTED PLASMA

I enclose copies of all correspondence to date concerning the recall of blood products produced from CJD-affected plasma. The companies involved are Baxter (Hyland Division), California, U.S.A. and Laboratoire Francais du fractionnement et des Biotechnologies, (L.F.B.) in France.

The 2 batches implicated of Haemofil-M were not supplied to the UK by Baxter. However, some fraction IV paste from the lot affected was supplied to Miles Inc. (Cutter Laboratories) of Berkley, California. I have asked Bayer to follow this up for any implications in the UK.

L.F.B. supplied Factor VIII THP and Factor IX to 3 centres in the UK, Cardiff and St Thomas' have used all the stock, Aberdeen still has all the stock unused and has placed it in quarantine.

I will inform you of any subsequent developments.

Dear Top page only to GRO-C 25/11/94.
Nigel G.

GRO-C

Nigel M. Goulding
MCA-I&E
Room 1816 MT
Ext GRO-C

Mr Goulding
Nigel,
On reflection and following our discussion yesterday, I think it would be useful — since we are Rapporteur for Haemofil-M — to seek information from the Company about the implications for other Member States in addition to the UK. Whatever information is then provided, I would suggest, should be circulated by FAX to all Member States to keep them adequately informed. Also, colleagues in post-Licensing Division should be made aware of this recall to keep them informed.

GRO-C

25/11/94.
cc Nigel (all parties)
file CMM/CM/Haemofil